Immunosuppression for dual kidney transplantation with marginal organs: the old is better yet. 2007

J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
Department of Nephrology, Hospital Universitari de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, 08907 I'Hospitalet de Llobregat, Barcelona, Spain.

Immunosuppressive protocols in dual kidney transplantation (DKT) are based on calcineurin inhibitors (CNI). We wonder whether a CNI-free immunosuppression can improve outcome in older patients receiving a DKT with marginal donor organs. Thirty-six were treated with CsA, MMF and prednisone (CsA group) and 42 with rATG, SRL, MMF and prednisone (SRL group). Incidence of delayed graft function and acute rejection was 44% and 11% in the CsA group, and 40% and 8% in the SRL group. CMV infection incidence was low in both protocols. Three-year patient survival was 89% in the CsA and 76% in the SRL group. One- and 3-year graft survival after censoring for dead with a functioning allograft was 94.2% and 94% in CsA and 95% and 90% in SRL, respectively. Renal function was similar in both groups whereas proteinuria was higher in the SRL group. Uninephrectomy due to graft thrombosis or urinary-related complications was numerically higher in the SRL (21%) than in the CsA group (8%) (p = 0.13) and it was associated with renal failure and proteinuria. In DKT, a new induction immunosuppressive protocol based on rATG, SRL, MMF and prednisone does not offer any advantage in comparison to the old CsA, MMF and prednisone.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
December 2002, Transplantation proceedings,
J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
January 2007, Transplantation proceedings,
J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
July 2016, Annals of transplantation,
J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
August 1973, Lancet (London, England),
J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
January 2010, European journal of medical research,
J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
January 2019, Frontiers in immunology,
J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
October 2009, The Journal of urology,
J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
October 2008, Nephrologie & therapeutique,
J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
March 2011, Circulation. Heart failure,
J M Cruzado, and O Bestard, and L Riera, and J Torras, and S Gil-Vernet, and D Serón, and I Rama, and F Moreso, and A Martínez-Castelao, and J M Grinyó
February 2022, Current opinion in organ transplantation,
Copied contents to your clipboard!